Почетна › Многи мијелом › Kolorado › Denver
Kliničke studije za Многи мијелом u gradu Denver, CO
26 studija za Многи мијелом traži učesnike na lokacijama u gradu Denver i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Colorado Blood Cancer Institute, Denver
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Тражи се учесникФаза 3
- Research Site, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Тражи се учесникФаза 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Тражи се учесникФаза 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Research Site, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- CBCI, Colorado Blood Cancer Institute, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Тражи се учесникФаза 1
- Research Site, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Тражи се учесникФаза 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Тражи се учесникФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Тражи се учесникФаза 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Colorado Blood Cancer Institute, Denver
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Houston, TX39 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
- Baldwin Park, CA23 студија
Ostale studije u gradu Denver
- Рак дојке26 студија
- Немалоклетни карцином плућа25 студија
- Метастатски карцином25 студија
- Колоректални карцином22 студија
- Меланом19 студија
- Рак простате19 студија
- Рак јајника17 студија
- Карцином ендометријума15 студија
- Рак (све врсте)15 студија
- Рак плућа15 студија
- Не-Ходжкинов лимфом14 студија
- Рак панкреаса13 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.